Skip to main content

and
  1. No Access

    Article

    Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

    Purpose We investigated the combination of the MEK inhibitor, cobimetinib, and the pan-PI3K inhibitor, pictilisib, in an open-label, phase Ib study. Experimental Design Patients with advanced solid tumors were en...

    Geoffrey I. Shapiro, Patricia LoRusso, Eunice Kwak in Investigational New Drugs (2020)

  2. No Access

    Article

    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

    Background We sought to determine the recommended phase II dose (RP2D) and schedule of GSK2141795, an oral pan-AKT kinase inhibitor. Patients and Methods Patients with solid tumors were enrolled in the dose-escal...

    Carol Aghajanian, Katherine M. Bell-McGuinn in Investigational New Drugs (2018)

  3. No Access

    Article

    A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

    Introduction The PI3 kinase (PI3K) pathway is a commonly dysregulated pathway in cancers and is an attractive target for antitumor therapy. BEZ235 is a potent, highly specific and selective dual ...

    Johanna C. Bendell, Carla Kurkjian, Jeffrey R. Infante in Investigational New Drugs (2015)

  4. Article

    Open Access

    Targeted enzyme prodrug therapy for metastatic prostate cancer – a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase

    Enzyme prodrug therapy shows promise for the treatment of solid tumors, but current approaches lack effective/safe delivery strategies. To address this, we previously developed three enzyme-containing fusion p...

    Katrin P Guillen, Carla Kurkjian, Roger G Harrison in Journal of Biomedical Science (2014)

  5. Article

    Open Access

    A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

    Background ME-143, a second-generation tumor-specific NADH oxidase inhibitor, is broadly active against human cancers in vitro and in vivo. This first-in-human dose-escalation study evalu...

    Shubham Pant, Howard A. Burris III, Kathleen Moore in Investigational New Drugs (2014)

  6. No Access

    Article

    Symptomatic metastases to the pituitary infundibulum resulting from primary breast cancer

    Metastatic spread into the brain is not infrequently seen in association with epithelial neoplasms such as lung and breast cancer, among others. In the majority of cases such spread entails a poor prognosis. M...

    Carla Kurkjian, Jess F. Armor in International Journal of Clinical Oncology (2005)